MDxHealth Q4 2022 Earnings Report

MDxHealth EPS Results

• Actual EPS: -$11.00
• Consensus EPS: -$7.50
• Beat/Miss: Missed by -$3.50
• One Year Ago EPS: N/A

MDxHealth Revenue Results

• Actual Revenue: $12.89 million
• Expected Revenue: $14.76 million
• Beat/Miss: Missed by -$1.87 million
• YoY Revenue Growth: N/A

MDxHealth Announcement Details

• Quarter: Q4 2022
• Date: 3/8/2023
• Time: N/A

MDxHealth (NASDAQ:MDXH), a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.